BR9713479A - Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico. - Google Patents

Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico.

Info

Publication number
BR9713479A
BR9713479A BR9713479-1A BR9713479A BR9713479A BR 9713479 A BR9713479 A BR 9713479A BR 9713479 A BR9713479 A BR 9713479A BR 9713479 A BR9713479 A BR 9713479A
Authority
BR
Brazil
Prior art keywords
acid
pharmaceutical preparation
stearidonic
eicosapentaenoic
eicosapentaenoic acid
Prior art date
Application number
BR9713479-1A
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621294.9A external-priority patent/GB9621294D0/en
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of BR9713479A publication Critical patent/BR9713479A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"PREPARAçãO FARMACêUTICA COMPREENDENDO áCIDO EICOSAPENTAENóICO E/OU áCIDO ESTEARIDÈNICO"<D>. Uma preparação farmacêutica para o tratamento de esquizofrenia e/ou disquenia tardia, usando um óleo compreendendo ácido eicosapentaenóico (EPA) e/ou ácido estearidónico (SA) em quantidades de mais do que 20%, de preferência, mais do que 40% e, muito preferivelmente, mais do que 70% em peso do total (de preferência, do total de insaturados) de ácidos graxos presentes.
BR9713479-1A 1996-10-11 1997-10-07 Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico. BR9713479A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621294.9A GB9621294D0 (en) 1996-10-11 1996-10-11 Fatty acid treatment
GBGB9626062.5A GB9626062D0 (en) 1996-10-11 1996-12-16 Fatty acid treatment
PCT/GB1997/002738 WO1998016216A1 (en) 1996-10-11 1997-10-07 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Publications (1)

Publication Number Publication Date
BR9713479A true BR9713479A (pt) 2000-04-11

Family

ID=26310221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713479-1A BR9713479A (pt) 1996-10-11 1997-10-07 Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico.

Country Status (25)

Country Link
US (5) US6331568B1 (pt)
EP (1) EP0956013B1 (pt)
JP (1) JP4151853B2 (pt)
KR (2) KR20060061409A (pt)
CN (1) CN1109543C (pt)
AT (1) ATE236627T1 (pt)
AU (1) AU731692C (pt)
BR (1) BR9713479A (pt)
CA (1) CA2268257C (pt)
CZ (1) CZ293704B6 (pt)
DE (1) DE69720787T2 (pt)
DK (1) DK0956013T3 (pt)
ES (1) ES2195175T3 (pt)
HK (1) HK1020316A1 (pt)
ID (1) ID21473A (pt)
IL (1) IL129367A0 (pt)
IS (1) IS2180B (pt)
NO (1) NO326926B1 (pt)
NZ (1) NZ334852A (pt)
PL (1) PL190181B1 (pt)
PT (1) PT956013E (pt)
SK (1) SK285210B6 (pt)
TR (1) TR199900786T2 (pt)
TW (1) TW429145B (pt)
WO (1) WO1998016216A1 (pt)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060061409A (ko) * 1996-10-11 2006-06-07 스카리스타 리미티드 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일
ATE320803T1 (de) * 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
FR2788437B1 (fr) * 1999-01-14 2006-08-11 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9904895D0 (en) * 1999-03-03 1999-04-28 Scarista Limited Regulators of coenzyme-A-independent transacylase as psychotropic drugs
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
WO2002092779A2 (en) * 2001-05-17 2002-11-21 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
DE60221287T4 (de) 2001-11-08 2009-06-25 Atrium Medical Corp. Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8987263B2 (en) * 2002-10-10 2015-03-24 Meir Shinitzky Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CH698539A8 (de) 2003-08-18 2009-10-15 Btg Int Ltd Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose.
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9801913B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Barrier layer
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
US8263102B2 (en) * 2004-09-28 2012-09-11 Atrium Medical Corporation Drug delivery coating for use with a stent
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US7550286B2 (en) * 2004-11-04 2009-06-23 E. I. Du Pont De Nemours And Company Docosahexaenoic acid producing strains of Yarrowia lipolytica
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
KR20070090928A (ko) * 2004-11-19 2007-09-06 마텍 바이오싸이언스스 코포레이션 장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
CN103211807A (zh) * 2005-07-08 2013-07-24 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
CA2626030A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
CA2634139C (en) * 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
EP1983977A4 (en) * 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20100130611A1 (en) * 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
CN101663031A (zh) * 2007-02-20 2010-03-03 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备方法和使用方法
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
US8323935B2 (en) * 2007-10-03 2012-12-04 E I Du Pont De Nemours And Company Optimized strains of Yarrowia lipolytica for high eicosapentaenoic acid production
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009086281A1 (en) * 2007-12-21 2009-07-09 Martek Biosciences Corporation Method for preparation of oxylipins
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US20110166229A1 (en) * 2008-09-09 2011-07-07 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
LT3037089T (lt) 2009-02-10 2020-01-10 Amarin Pharmaceuticals Ireland Limited Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
GB0904300D0 (en) 2009-03-12 2009-04-22 Amarin Neuroscience Ltd Essential fatty acid compounds
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
US8372465B2 (en) 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
RU2728825C2 (ru) * 2010-03-04 2020-07-31 Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
RS61557B1 (sr) 2012-06-29 2021-04-29 Amarin Pharmaceuticals Ie Ltd Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3102227A4 (en) 2014-02-07 2017-09-27 University Of Utah Research Foundation Combination of creatine, an omega-3 fatty acid, and citicoline
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016063959A1 (ja) * 2014-10-24 2016-04-28 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
ES2607715B1 (es) * 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
CH678181A5 (pt) * 1989-05-22 1991-08-15 Nestle Sa
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
DK0457950T3 (da) * 1990-05-23 1994-03-07 Nestle Sa Anvendelse af stearidonsyre til behandling af inflammatorisk betingede sygdomme
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
KR20060061409A (ko) * 1996-10-11 2006-06-07 스카리스타 리미티드 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일
US6590846B2 (en) * 1999-05-21 2003-07-08 Matsushita Electric Industrial Co., Ltd. Recordable optical disk

Also Published As

Publication number Publication date
TR199900786T2 (xx) 1999-07-21
NO326926B1 (no) 2009-03-16
AU731692B2 (en) 2001-04-05
AU731692C (en) 2001-10-11
ID21473A (id) 1999-06-17
NO991635D0 (no) 1999-04-06
KR100657642B1 (ko) 2006-12-19
SK44899A3 (en) 2000-08-14
DE69720787D1 (de) 2003-05-15
CA2268257A1 (en) 1998-04-23
IL129367A0 (en) 2000-02-17
CN1109543C (zh) 2003-05-28
EP0956013A1 (en) 1999-11-17
US20030045578A1 (en) 2003-03-06
CZ293704B6 (cs) 2004-07-14
JP2001503743A (ja) 2001-03-21
JP4151853B2 (ja) 2008-09-17
TW429145B (en) 2001-04-11
HK1020316A1 (en) 2000-04-14
CZ115499A3 (cs) 1999-08-11
DE69720787T2 (de) 2004-03-18
US20020065319A1 (en) 2002-05-30
DK0956013T3 (da) 2003-08-04
PL190181B1 (pl) 2005-11-30
US20040048927A1 (en) 2004-03-11
WO1998016216A1 (en) 1998-04-23
KR20000049016A (ko) 2000-07-25
IS5017A (is) 1999-03-30
PT956013E (pt) 2003-08-29
US6331568B1 (en) 2001-12-18
AU4566797A (en) 1998-05-11
ATE236627T1 (de) 2003-04-15
CN1233955A (zh) 1999-11-03
US20040014810A1 (en) 2004-01-22
PL333423A1 (en) 1999-12-06
IS2180B (is) 2006-12-15
KR20060061409A (ko) 2006-06-07
NZ334852A (en) 2001-05-25
CA2268257C (en) 2008-05-20
EP0956013B1 (en) 2003-04-09
US6624195B2 (en) 2003-09-23
SK285210B6 (sk) 2006-09-07
NO991635L (no) 1999-06-07
ES2195175T3 (es) 2003-12-01

Similar Documents

Publication Publication Date Title
BR9713479A (pt) Preparação farmacêutica compreendendo ácido eicosapentaenóico e/ou ácido estearidÈnico.
ES2053990T3 (es) Composiciones de acidos grasos esenciales.
NO940277L (no) Triglycerider og blandinger av slike
KR940018091A (ko) 불포화 지방산을 포함하는 처방
FR2754820B1 (fr) Le (-)hydroxycitrate de magnesium, procede de preparation, applications, et compositions notamment pharmaceutiques le renfermant
MY109928A (en) Fatty acid treatment
IS6644A (is) Meðferðarblöndur fitusýra
NZ299464A (en) Use of gamma linolenic or dihomogamma linolenic acid in the treatment of Huntington&#39;s Chorea
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
YU89891A (sh) SMEŠE TGF-beta
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
ES2171535T3 (es) Producto nutritivo utilizado en el tratamiento de la colitis ulcerosa y su uso.
DE60008127D1 (de) Diät mit hohem lipidgehalt
ID15895A (id) Formulasi untuk menurunkan kolesterol darah dan penyerapan lemak berbagai fungsi
NO932984L (no) Fettsyrebehandling
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
HUP0000419A2 (hu) Eikozapentaénsavat és/vagy sztearidonsavat tartalmazó gyógyászati készítmény
TH58453B (th) การบำบัดของกรดไขมัน
TH15810A (th) สูตรผสมที่มีกรดแฟททีชนิดไม่อิ่มตัว
TH58453A (th) การบำบัดของกรดไขมัน

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SCOTIA HOLDINGS PLC (GB)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 049365/RJ DE 03/09/2003.

B25A Requested transfer of rights approved

Owner name: SCARISTA LIMITED (GB)

Free format text: TRANSFERIDO DE: SCOTIA HOLDINGS PLC

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO REOLHIMENTO DA 5A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1877 DE 26/12/2006 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.